Research
Hormonal
Impaired BCAA metabolism, specifically reduced activity of enzymes like BCATm and BCKDC, leads to the accumulation of BCAAs and their toxic intermediates, contributing to insulin resistance and mitochondrial dysfunction.
If you have insulin resistance, your body might not be breaking down BCAAs efficiently, leading to high levels in your blood. This is not necessarily because you are eating too much protein, but because your metabolic enzymes are less active. Focus on improving overall metabolic health rather than just restricting protein.
ModerateSupportsMEDIUM confidence
defective BCAA oxidative metabolism might occur in obesity, leading to a further accumulation of BCAAs and toxic intermediates. ... In the adipose tissue of patients with obesity and T2DM with insulin resistance, the expression of genes encoding the enzymes of BCAA metabolism is significantly decreased... leading to an increased plasma level of BCAAs.
Why this rating
Based on mechanistic studies and observations in T2DM patients.
Source
The Emerging Role of Branched-Chain Amino Acids in Insulin Resistance and Metabolism
Mee‐Sup Yoon · Nutrients · 2016
DOI 10.3390/nu8070405
narrative_reviewCited 431×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Elevated plasma levels of branched-chain amino acids (BCAAs) are associated with an increased risk of insulin resistance and type 2 diabetes, potentially through the persistent activation of mTORC1 and subsequent serine phosphorylation of IRS-1.Moderate
- BCAA supplementation or high BCAA diets can improve metabolic parameters such as body composition, glucose tolerance, and insulin sensitivity in specific contexts, such as in high-fat diet-fed mice or by stimulating protein synthesis.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →